FDA Approves Iberdomide for Relapsed/Refractory Multiple Myeloma

The FDA has granted accelerated approval to iberdomide, a novel CELMoD, for relapsed/refractory multiple myeloma in combination with daratumumab and dexamethasone. This marks the first myeloma approval based primarily on measurable residual disease (MRD) data, rather than traditional endpoints. The therapy is for adults who have received at least one prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent.